Maximum Fit Magazine

In women who used unopposed postmenopausal estrogen from ages 50 to 60, the cumulative risk increased by 23% compared with women who had never used hormones. The risk was increased by 67% in those who used estrogen plus progestin. It is finally, gradually coming out. All the old ERT and surgical menopause studies of long term hormone risks and benefits in the past cannot be applied to the majority of women entering menopause today. ERT does not equal HRT OK, hands up, what will the risk of bc be once the nurses get old enough to have taken HRT for longer than 10 years? How much do we know about long term HRT in intact women anyway? Peanuts! [ This bc risk study covers other risk factors too btw, ( alcohol use, benign breast disease etc) I just quoted  the hormone use part of the story. ] Kathryn This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Byrne C, Connolly JL, Colditz GA, Schnitt SJ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. [Record supplied by publisher] BACKGROUND: A history of proliferative benign breast disease has been shown to increase the risk of developing breast carcinoma, but, to the authors' knowledge, how postmenopausal exogenous female hormone use, in general, has affected breast carcinoma risk among women with a history of proliferative breast disease with or without atypia has not been well established. METHODS: In the current case-control study, nested within the Nurses' Health Study, benign breast biopsy slides of 133 postmenopausal breast carcinoma cases and 610 controls with a history of benign breast disease, were reviewed. Reviewers had no knowledge of case status. RESULTS: Women with proliferative disease without atypia had a relative risk for postmenopausal breast carcinoma of 1.8 (95%, confidence interval [CI]: 1.1 to 2.8), and women with atypical hyperplasia had a relative risk of 3.6 (95%, CI: 2.0 to 6.4) compared with women who had nonproliferative benign histology. Neither current postmenopausal use of exogenous female hormones nor long term use for 5 or more years further increased the risk of breast carcinoma in the study population beyond that already associated with their benign histology. CONCLUSIONS: Women who had proliferative benign breast disease, with or without atypia, were at moderately to substantially increased risk of developing postmenopausal breast carcinoma compared with women who had nonproliferative benign conditions. In the current study, postmenopausal exogenous female hormone use in general did not further increase the breast carcinoma risk for women with proliferative benign breast disease. However, the analysis did not exclude the possibility of increased risk with a particular hormone combination or dosage. Copyright 2000 American Cancer Society. PMID: 11066044 Kathryn This e-mail address is being protected from spam bots, you need JavaScript enabled to view it - Hide quoted text -- Show quoted text -

<snip Cancer 2000 Nov 15;89(10):2046-2052 Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Byrne C, Connolly JL, Colditz GA, Schnitt SJ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. [Record supplied by publisher] BACKGROUND: A history of proliferative benign breast disease has been shown to increase the risk of developing breast carcinoma, but, to the authors' knowledge, how postmenopausal exogenous female hormone use, in general, has affected breast carcinoma risk among women with a history of proliferative breast disease with or without atypia has not been well established. METHODS: In the current case-control study, nested within the Nurses' Health Study, benign breast biopsy slides of 133 postmenopausal breast carcinoma cases and 610 controls with a history of benign breast disease, were reviewed. Reviewers had no knowledge of case status. RESULTS: Women with proliferative disease without atypia had a relative risk for postmenopausal breast carcinoma of 1.8 (95%, confidence interval [CI]: 1.1 to 2.8), and women with atypical hyperplasia had a relative risk of 3.6 (95%, CI: 2.0 to 6.4) compared with women who had nonproliferative benign histology. Neither current postmenopausal use of exogenous female hormones nor long term use for 5 or more years further increased the risk of breast carcinoma in the study population beyond that already associated with their benign histology. CONCLUSIONS: Women who had proliferative benign breast disease, with or without atypia, were at moderately to substantially increased risk of developing postmenopausal breast carcinoma compared with women who had nonproliferative benign conditions. In the current study, postmenopausal exogenous female hormone use in general did not further increase the breast carcinoma risk for women with proliferative benign breast disease. However, the analysis did not exclude the possibility of increased risk with a particular hormone combination or dosage. Copyright 2000 American Cancer Society. PMID: 11066044 Kathryn This e-mail address is being protected from spam bots, you need JavaScript enabled to view it Thanks for posting this stuff, Kathryn. Frederica Sent via Deja.com http://www.deja.com/ Before you buy.

Yes, Kathryn, a big thank you for all the searching and posting you do... Martha